| Impaired glucose tolerance(IGT) ia a state between normal glucose tolerance (NGT) and type 2 diabetes mellitus(DM). Every year About 20%-50% IGT patients in adults convert to type 2 DM patients. So the intervention in IGT patients is significant. Acarbose , a -Glucosidase inhibitor , can decrease postprandial hyperglycemia. Some studies inferred that inflammation might play an important role in the pathogenesis of type 2 DM, and type 2 DM may be a kind of acute-phase response induced by immune system and mediated by cytokins. In addition, recently the role of free fatty acid in the pathogenesis of type 2 DM is emphasized, and the theory of Diabetes Mellipidtus has been proposed. So the correction of high serum FFA may be significant in the prevention of type 2 DM. The purpose of this study is to investigate the effect of acarbose treatment in IGT subjects on Serum C-Reactive Protein Level and Free Fatty Acid Spectrum.1. The Effect of Acarbose Treatment on Serum C-ReactvieLevels in IGT SubjectsAIMS Inflammation might play an important role in the pathogenesis of type 2 DM. CRP is a presentitive acute-phase serum protein. The serum CRP concentrations in various glucose tolerance subjects were investigated, and the serum CRP concentrations were observed in IGT subjects treatedwith acarbose. SUBJETCTS AND METHODS A total of 154 subjects (age 53.74+9.02 years, 80 males, 74 females) participated in the study. According to the ADA criteria 44 (23males, 21 females) were NGT, 89 (45 males, 44 females) were IGT and 21 (12 males, 9 females) were type 2 DM, respectively.The clinical data and serum of 60 IGT subjects came from a multicenter, randomized, doubleblind, placebo-controlled study. The IGT subjects received either 150 mg acarbose daily or placebo for 16 weeks.The serum CRP concentration was detected with immunoscattering assay. RESULTS l.The concentration of serum CRP [median(25, 75 %)]was 4. 60(4. 10-5. 25)mg/L in NGT subjects, 5. 25 (4. 50-6. 00)mg/L in IGT subjects, 5.70 (5.20-7.50) mg/L in type 2 DM (p <0.001).The serum CRP level was positively correlated with 2h blood glucose ( r=0.360, P=0.000 ) , HbAlc(r=0.272, P=0. 035), TC (r=0.168, P=0. 036), TG (r=0. 270, P=0. 001) . 2. The serum CRP level [median(25, 75 %)] in IGT subjects treated with acarbose for 16 weeks was decreased from 5. 35 (4. 40-6. 60) mg/L to 4. 90 (4. 40-5. 50) mg/L(p<0.05), and from 5.25 (4.60-5.80) mg/L to 5.05 (4.60-6.0) mg/L(p>0.05)in placebo group (F=2.182, p<0.05) .2. The Effect of Acarbose Treatment on Serum Free FattyAcid Spectrum in IGT SubjectsAIMS Free Fatty Acid(FFA) may play an important role in the pathogenesis of type 2 DM, and correction of high serum FFA may be significant in the prevention of type 2 DM.It was investigated whether acarbose, an a -Glucosidase inhibitor, could reduce total serum FFA and its ingredient level in IGT subjects. SUBJETCTS AND METHODS A total of 30 IGT subjects (age 54.1+8.6 years, 13 males, 17 femals) diagnosed by ADA9criteria participated in the study. The clinical data and serum of the subjects came from a multicenter, randomized, doubleblind, placebo-controlled study. The IGT subjects received either 150 mg acarbose daily or placebo for 16 weeks. The 120g noodles tests were carried out before and after treatment. Serum FFA and its ingredient level were detected with Gas Chromatography Assay. RESULTS At the end of the study, the FBG level was decreased from 5.58 + 0.74 mmol/L to 4.91+ 0. 53mmol/L in acarbose group, while it was increased from 5.89 + 0.83 mmol/L to 5.90 + 0.86 mmol/L in placebo group. The 2hPBG was decreased from 7.69 + 1.49 mmol/L to 6. 25 + 0. 69mmol/L in acarbose group, while it was increased from 9. 51 + 1. 52mmol/L to 10. 71 + 1. 42 mmol/L in placebo group. The postprandial total serum FFA was decreased from 1033. 78 + 566. 81umol/L to 856. 7 + 379. 3umol/L in acarbose group, while it was increased from 988. 0 + 268. 3umol/L to 1112.4 + 302.3 umol/L in placebo group. The fasting total serum FFA was decreased slightly in acarbose group,...
|
PDF Full Text Request